News
Algeta Announces First US Patient Randomized In ALSYMPCA Phase III Study At Tulane Cancer Center, New Orleans Medical News Today
View ArticleAlgeta shares spike on promising prostate cancer drug data
Algeta shares spike on promising prostate cancer drug data Fierce Biotech
View ArticleFirst Phase III trial of an alpha-pharmaceutical
First Phase III trial of an alpha-pharmaceutical eurekalert.org
View ArticleBayer Drug Hailed As Prostate Cancer Game Changer
Bayer Drug Hailed As Prostate Cancer Game Changer TheStreet.com
View ArticleBlockbuster buzz: 15 top therapies in late-stage development
Blockbuster buzz: 15 top therapies in late-stage development Fierce Biotech
View ArticleAlgeta Sees ’Widespread’ Interest in Thorium Cancer Technology
Algeta Sees ’Widespread’ Interest in Thorium Cancer Technology Bloomberg
View ArticleBayer, Algeta Win U.S. Approval for Prostate Cancer Drug
Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug Bloomberg
View ArticleNorway's Algeta says prostate cancer drug makes solid U.S. debut
Norway's Algeta says prostate cancer drug makes solid U.S. debut Reuters
View ArticleBayer bids $2.4 billion for Norwegian cancer drug partner Algeta
Bayer bids $2.4 billion for Norwegian cancer drug partner Algeta Yahoo/Reuters
View ArticleBayer wins Norway cancer firm Algeta with raised $2.9 billion offer
Bayer wins Norway cancer firm Algeta with raised $2.9 billion offer Reuters
View ArticlePulse of J.P. Morgan 2014: Interviews with 17 biopharma execs
Pulse of J.P. Morgan 2014: Interviews with 17 biopharma execs Fierce Biotech
View ArticleBayer Set to Acquire Algeta in First Quarter
Bayer Set to Acquire Algeta in First Quarter Marketwatch
View ArticleBayer says takeover offer for Algeta successful
Bayer says takeover offer for Algeta successful Reuters
View Article
